ClinicalTrials.gg
CompletedNCT06179342Updated May 7, 2024

Multiple Breath Washout as a Method for Diagnosing Lung Diseases

An observational study in Pulmonary Fibrosis, COPD and Asthma, sponsored by Wissenschaftliches Institut Bethanien e.V. Completed at 1 site in Germany. Per ClinicalTrials.gov, last updated 2024-05-07.

Sponsored by Wissenschaftliches Institut Bethanien e.V · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
90
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 25 studies in Pulmonary Fibrosis with a site in Germany — 4 open to participants now, 8 under way, 3 of them phase 3. Pulmonary Fibrosis · Germany.

Started
2021
with 2 others
Observational
4 of 25
2 open now
Registered
21st of 25
by date

Among the 25 studies in Pulmonary Fibrosis with a site in Germany, this one is one of 3 that started in 2021, is one of 4 observational ones, and was the 21st registered.

Pulmonary Fibrosis

342 studies on the registry are indexed under Pulmonary Fibrosis; 98 are open to participants now.

Browse Pulmonary Fibrosis studies →

Open to participants now

4 of the 25 studies in Pulmonary Fibrosis with a site in Germany are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 71 Pulmonary Fibrosis studies recruiting now, 41 (58%) set no upper age limit and 4 (6%) stop at 75 or younger; 8 take children under 18; 12 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies in Pulmonary Fibrosis with a site in Germany, or all of them as a file.
02

Study summary

Comparison of the new multiple-breath washout method (ndd Medizintechnik Zürich, Trueflow™/Truecheck™) with established methods of lung function diagnostics in patients with idiopathic pulmonary fibrosis, chronic obstructive pulmonary disease, asthma and cardiopulmonary healthy individuals.

Read the detailed description

This diagnostic, prospective, clinical study aims to investigate whether the lung function data measured with the EasyOnePro®LAB device correlates with the lung function data from established measurement methods used in routine clinical practice. It is to be investigated whether the EasyOnePro®LAB measurement leads to equivalent results even with a shorter measurement duration due to an improved evaluation. This is relevant for a broader clinical application in the future.

It will also be tested whether the fact that the EasyOnePro®LAB measurement can be carried out largely independently of the employee also leads to better reproducibility of the results. To this end, the intra-individual deviations in repeated measurements will be compared between the methods.

03

Conditions studied

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients admitted to the study center with one of the above-mentioned diseases

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years
  • existing consent
  • confirmed diagnosis of one of the following diseases
  • idiopathic pulmonary fibrosis (IPF), confirmed according to the guidelines
  • (COPD) with/without emphysema
  • bronchial asthma
  • or patients who are admitted with suspected cardiopulmonary dysfunction (e.g. with unclear dyspnoea) and in whom there is no evidence of cardiopulmonary dysfunction during the diagnostic process (comparison group of "healthy" patients).
  • Indication for routine performance of the following pulmonary function tests during the current inpatient stay: Whole Body Plethysmography \& Diffusion Capacity of the Lung (single-breath)

Exclusion criteria

Exclusion Criteria:

  • Age \< 18 years
  • Simultaneous presence of at least two of the following diseases (IPF, /emphysema, asthma, pulmonary arterial hypertension)
  • any medical, psychological or other condition that restricts the patient's ability to give for voluntary participation in this trial
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
90 participants (actual)
Patient registry
No

Groups and cohorts

  • Cardiopulmonary healthy

    Patients in whom there is no evidence of cardiopulmonary dysfunction in the course of diagnostics

    Diagnostic Test: Multiple-Breath-Washout

  • Idiopathic pulmonary fibrosis

    idiopathic pulmonary fibrosis (IPF), confirmed according to the guidelines

    Diagnostic Test: Multiple-Breath-Washout

  • Chronic obstructive pulmonary disease

    Chronic obstructive pulmonary disease (COPD) with/without emphysema

    Diagnostic Test: Multiple-Breath-Washout

  • Asthma bronchiale

    Diagnostic Test: Multiple-Breath-Washout

Interventions

  • Diagnostic testMultiple-Breath-Washout

    One additional diagnostic test is performed using the Multiple-Breath-Washout technology

06

What researchers measure

Primary outcomes

  1. Lung Clearance Index

    comparison of the lung clearance index of the different patient groups

    Time frame: immediately ofter the procedure

07

Study locations

1 site
  • Wissenschaftliches Institut Bethanien e.V.
    Solingen, NRW 42699, Germany
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2021 to primary completion in Mar 2024, 32 months.

Of 60 observational studies under Pulmonary Fibrosis, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 111. This study's 32 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 6, 2023
First posted
Dec 21, 2023
StartActual
Jun 21, 2021
Primary completionActual
Mar 1, 2024
CompletionActual
Mar 1, 2024
Last update
May 7, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 7, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06179342
Lead sponsor
Wissenschaftliches Institut Bethanien e.V
Collaborators
Boehringer Ingelheim, ndd Medizintechnik AG
Responsible party
Sponsor
First posted
Dec 21, 2023
Start date
Jun 21, 2021
Primary completion
Mar 1, 2024
Completion
Mar 1, 2024
Last update
May 7, 2024

Study contacts

Lars Hagmeyer, PD Dr.
principal investigator · Wissenschaftliches Institut Bethanien e.V

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion